"Protecting the drugs of tomorrow : competition and innovation in healthcare"* In a nutshell : In Novartis/GSK Oncology, the Commission extended its analysis of pipeline pharmaceutical products beyond those that are in advanced stages of development (phase III), to fully assess the impact of the merger on innovation competition. The case also presented novel issues regarding the design of a remedy involving third party rights, and the consideration of lines of treatment as an indicator of the extent of closeness of competition. In January 2015, the Commission cleared the EUR 16 billion acquisition of a GlaxoSmithKline ("GSK") portfolio of cancer treatments by Novartis , subject to conditions . One of the key roles of merger control in the pharmaceutical industry is to ensure
The EU Commission conditionally approves deals in the pharmaceutical sector extending its analysis of pipeline pharmaceutical products (Novartis / GSK)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.